Zentraxa is precision engineering biomaterials, pushing the boundaries of biopolymer synthesis to develop sustainable, performance-enhancing ingredients for everyday products. Its proprietary technological platform (Zentide) overcomes the biodesign limits of existing, conventional peptide synthesis by designing, producing and testing complex, novel peptides with one universal process. Zentraxa creates bespoke solutions for a range of industries by combining key features from different naturally-occurring proteins, such as stiffness, adhesion or thermal stability.

neo-fossil is developing new technology using cell engineering to help reverse the threat of climate change. By optimising biology, it is creating new fossils that harvest atmospheric carbon dioxide, storing it for centuries.

Extracellular is developing cell culture technologies to use the cell samples of living animals and plants to create sustainable alternatives to commercial products in the cosmetic, material and food industries. As a bioprocessing and manufacturing partner, it provides solutions from cell-line and scale-up development to facilitating routes to market, supporting other biotech companies seeking to develop greener consumer products such as cultivated meat, dairy products, leather, cotton and active ingredients for cosmetics.

Scarlet Therapeutics is developing a proprietary platform that generates novel red blood cell-based therapeutics (tRBCs) to treat a wide range of diseases. Its technologies are underpinned by learnings from decades of research including the groundbreaking RESTORE clinical study run by NHS Blood and Transplant and the University of Bristol, investigating transfusion of lab-grown blood into patients. By generating tRBCs with high levels of therapeutic proteins from cell lines rather than from donated stem cells, Scarlet Therapeutics aims to address significant efficacy and manufacturing issues faced in the field.

Extracellular is developing cell culture technologies to use the cell samples of living animals and plants to create sustainable alternatives to commercial products in the cosmetic, material and food industries. As a bioprocessing and manufacturing partner, it provides solutions from cell-line and scale-up development to facilitating routes to market, supporting other biotech companies seeking to develop greener consumer products such as cultivated meat, dairy products, leather, cotton and active ingredients for cosmetics.

CellVoyant is accelerating the development of novel stem cell-based therapies for chronic diseases. Its technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, enable advanced cell analytics and ultimately unlock the controllable manufacturing of any cell and tissue in the body at scale. Built on foundational research at the University of Bristol, CellVoyant works at the intersection of cell biology, computing, engineering and machine learning to carry out its mission.